Sulforaphane treatment of autism spectrum disorder (ASD)
Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, Zimmerman AW
Proceedings of the National Academy of Sciences of the United States of America · 312 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2014-10-13 · Proc Natl Acad Sci U S A · vol. 111 · número 43 · págs. 15550–15555
- Editorial
- National Academy of Sciences
- Citado
- 462 citas · más que el 100% de estudios similares · 15.7× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 41 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Autism Spectrum Disorder Research · Nuclear Receptors and Signaling · Child Nutrition and Feeding Issues
- Palabras clave
- Autism spectrum disorder, Sulforaphane, Spectrum (functional analysis), Autism, Psychology, Medicine, Psychiatry, Physics, Cancer research
- MeSH
- humans, isothiocyanates, sulfoxides, placebos, treatment outcome, social behavior, child development disorders, pervasive, adolescent, adult, male, young adult
7 autores
- Kanwaljit Singh🇺🇸Harvard University; University of Massachusetts Chan Medical School; Massachusetts General Hospital; Center for Autism and Related Disorders
- Susan L. Connors🇺🇸Harvard University; Massachusetts General Hospital; Center for Autism and Related Disorders
- Eric A. Macklin🇺🇸Harvard University; Massachusetts General Hospital
- Kirby D. Smith
- Jed W. Fahey🇺🇸Johns Hopkins University; Johns Hopkins Medicine
- Paul Talalay🇺🇸Johns Hopkins University; Johns Hopkins Medicine
- Andrew W. Zimmerman🇺🇸Harvard University; University of Massachusetts Chan Medical School; Massachusetts General Hospital; Center for Autism and Related Disorders
Resumen
El texto original del estudio, en el idioma en que se publicó.
Autism spectrum disorder (ASD), characterized by both impaired communication and social interaction, and by stereotypic behavior, affects about 1 in 68, predominantly males. The medico-economic burdens of ASD are enormous, and no recognized treatment targets the core features of ASD. In a placebo-controlled, double-blind, randomized trial, young men (aged 13-27) with moderate to severe ASD received the phytochemical sulforaphane (n = 29)--derived from broccoli sprout extracts--or indistinguishable placebo (n = 15). The effects on behavior of daily oral doses of sulforaphane (50-150 µmol) for 18 wk, followed by 4 wk without treatment, were quantified by three widely accepted behavioral measures completed by parents/caregivers and physicians: the Aberrant Behavior Checklist (ABC), Social Responsiveness Scale (SRS), and Clinical Global Impression Improvement Scale (CGI-I). Initial scores for ABC and SRS were closely matched for participants assigned to placebo and sulforaphane. After 18 wk, participants receiving placebo experienced minimal change (<3.3%), whereas those receiving sulforaphane showed substantial declines (improvement of behavior): 34% for ABC (P < 0.001, comparing treatments) and 17% for SRS scores (P = 0.017). On CGI-I, a significantly greater number of participants receiving sulforaphane had improvement in social interaction, abnormal behavior, and verbal communication (P = 0.015-0.007). Upon discontinuation of sulforaphane, total scores on all scales rose toward pretreatment levels. Dietary sulforaphane, of recognized low toxicity, was selected for its capacity to reverse abnormalities that have been associated with ASD, including oxidative stress and lower antioxidant capacity, depressed glutathione synthesis, reduced mitochondrial function and oxidative phosphorylation, increased lipid peroxidation, and neuroinflammmation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.